Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, announced its participation in the upcoming Sidoti Micro-Cap Virtual Investor Conference. CEO and Chairman Robert Bitterman will present on May 22, 2025, at 10:00 AM ET, providing updates on the company's proprietary INTASYL gene silencing technology and progress on their ongoing clinical trial of PH-762 for skin cancer treatment.

The presentation will be accessible via webcast, and Bitterman will also host one-on-one meetings with investors during the conference on May 21-22, 2025. Registration for both the presentation and individual meetings is free and available through Sidoti's platform.

Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ET

Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Mr. Bitterman will also host one-on-one meetings with investors at the conference, taking place on May 21-22, 2025.

Phio's presentation will begin at 10 AM ET on May 22, 2025 and can be accessed live here:
   WEBCAST LINK FOR PHIO'S PRESENTATION: Webinar Registration - Zoom

Phio's one-on-one meetings with investors will take place on Wednesday and Thursday, May 21-22, 2025 and can be accessed here:
  REGISTRATION LINK FOR PRESENTATION OR ONE-ON-ONE MEETINGS: www.sidoti.com/events.
  Registration is free and you don't need to be a Sidoti client.

"All stakeholders, investors, and other individual followers are invited to join this presentation and register for one-on-one meetings to learn more about Phio Pharmaceuticals in our continuing pursuit of innovative pathways towards a cancer free future using our INTASYL technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

About Sidoti Events, LLC ("Events") and Sidoti & Company, LLC ("Sidoti")

In 2023, Sidoti & Company, LLC , Sidoti & Company, LLC (www.sidoti.com) formed an affiliate company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $200 million-$5 billion market cap range. Sidoti's coverage universe comprises approximately 160 equities, of which 50 percent participate in the firm's rapidly growing Company Sponsored Research ("CSR") program. Events is a leading provider of corporate access through the eight investor conferences it hosts each year. By virtue of its direct ties to Sidoti, Events benefits from Sidoti's small- and microcap-focused nationwide sales force, which has connections with approximately 2,500 institutional relationships in North America. This enables Events to provide multiple forums for meaningful interaction for small and microcap issuers and investors specifically interested in companies in the sector.

About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL^® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b clinical trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.

These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252526

FAQ

When is Phio Pharmaceuticals (PHIO) presenting at the Sidoti Micro-Cap Conference?

Phio Pharmaceuticals will present on May 22, 2025, at 10:00 AM ET at the Sidoti Micro-Cap Virtual Investor Conference.

What will be discussed in PHIO's Sidoti Conference presentation?

CEO Robert Bitterman will provide updates on Phio's INTASYL gene silencing technology and the ongoing clinical trial of PH-762 for skin cancer treatment.

How can investors attend PHIO's presentation at the Sidoti Conference?

Investors can register for free through www.sidoti.com/events to access both the presentation and schedule one-on-one meetings with management.

What is Phio Pharmaceuticals' main technology focus?

Phio Pharmaceuticals specializes in INTASYL gene silencing technology, developing siRNA therapeutics aimed at eliminating cancer.